Protagonist Therapeutics, Inc
PTGX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001377121
In the last 90 days, Protagonist Therapeutics, Inc insiders filed 0 open-market purchases and 2 sales; 346 institutions reported holding it in 13F filings for Q2 2026, worth $9.30B in total; Duquesne Family Office is the only superinvestor holding it.
Superinvestors holding PTGX, Q2 2026
1 superinvestor reports holding Protagonist Therapeutics, Inc on Form 13F, worth $25.6M in total. Weight is Protagonist Therapeutics, Inc's share of each 13F portfolio; actions compare shares with Q1 2026.
| Superinvestor | % of portfolio | Shares | Value | vs. previous quarter |
|---|---|---|---|---|
| Duquesne Family OfficeStanley Druckenmiller | 0.6% | 208,900 | $25.6M | Added+30.8% |
Moves by quarter
Superinvestors that opened, added to, trimmed or sold out of PTGX each quarter, comparing shares with the quarter before. A superinvestor that didn't file for a quarter isn't listed, and isn't counted as selling.
Q2 2026
1 superinvestor holding at quarter end
- Added
- Duquesne Family Office (+30.8%)
Q1 2026
1 superinvestor holding at quarter end
- Sold out
- Soros Fund Management
Q4 2025
2 superinvestors holding at quarter end
Q3 2025
1 superinvestor holding at quarter end